Evotec Announces Change in Management Board
Evotec SE (Frankfurt Stock Exchange: EVT, NASDAQ: EVO) announced that Dr Matthias Evers, Chief Business Officer, will step down effective 01 October 2024 to pursue opportunities outside the company. Evers, appointed on 01 May 2022, played a important role in establishing Evotec's biologics segment Just - Evotec Biologics and aiding the company's recovery from a cyber-attack. The Supervisory Board expressed gratitude for his contributions during challenging times.
Following Evers' departure, the responsibilities of the CBO function will be distributed across other Management Board functions. Dr Christian Wojczewski, CEO of Evotec, thanked Evers for his commitment and leadership, particularly highlighting his support during the transition period.
Evotec SE (Borsa di Francoforte: EVT, NASDAQ: EVO) ha annunciato che Dr Matthias Evers, Chief Business Officer, si dimetterà a partire dal 01 ottobre 2024 per perseguire opportunità al di fuori dell'azienda. Evers, nominato il 01 maggio 2022, ha svolto un ruolo importante nella creazione del segmento biologico di Evotec, Just - Evotec Biologics, e ha contribuito alla ripresa dell'azienda dopo un attacco informatico. Il Consiglio di Supervisione ha espresso gratitudine per il suo contributo durante tempi difficili.
In seguito alle dimissioni di Evers, le responsabilità della funzione CBO saranno distribuite tra le altre funzioni del Management Board. Dr Christian Wojczewski, CEO di Evotec, ha ringraziato Evers per il suo impegno e la sua leadership, sottolineando in particolare il suo supporto durante il periodo di transizione.
Evotec SE (Bolsa de Frankfurt: EVT, NASDAQ: EVO) anunció que el Dr. Matthias Evers, Director Comercial, dejará su cargo a partir del 01 de octubre de 2024 para perseguir oportunidades fuera de la empresa. Evers, nombrado el 01 de mayo de 2022, desempeñó un papel importante en el establecimiento del segmento biológico de Evotec, Just - Evotec Biologics, y ayudó a la recuperación de la empresa tras un ciberataque. El Consejo de Supervisión expresó su agradecimiento por sus contribuciones en tiempos difíciles.
Tras la salida de Evers, las responsabilidades de la función CBO se distribuirán entre otras funciones de la Junta Directiva. El Dr. Christian Wojczewski, CEO de Evotec, agradeció a Evers por su compromiso y liderazgo, destacando su apoyo durante el período de transición.
Evotec SE (프랑크푸르트 증권거래소: EVT, NASDAQ: EVO)는 Dr Matthias Evers, 최고 사업 책임자가 2024년 10월 1일부터 사임할 것이며 회사를 떠나 다른 기회를 추구할 것이라고 발표했습니다. Evers는 2022년 5월 1일에 임명되었으며, Evotec의 생물학적 부문인 Just - Evotec Biologics를 설립하는 데 중요한 역할을 했고 사이버 공격으로부터 회사의 회복에도 기여했습니다. 감독 위원회는 어려운 시기에 그의 기여에 감사의 뜻을 전했습니다.
Evers가 떠난 후, CBO 역할의 책임은 다른 경영진 기능에 분산될 예정입니다. Evotec의 CEO Dr Christian Wojczewski는 Evers의 헌신과 리더십에 감사하며 특히 전환기 동안 그의 지원을 강조했습니다.
Evotec SE (Bourse de Francfort: EVT, NASDAQ: EVO) a annoncé que Dr Matthias Evers, Directeur Commercial, quittera ses fonctions à compter du 01 octobre 2024 pour poursuivre des opportunités en dehors de l'entreprise. Evers, nommé le 01 mai 2022, a joué un rôle important dans l'établissement du segment biologique d'Evotec, Just - Evotec Biologics, et a contribué à la reprise de l'entreprise après une cyberattaque. Le Conseil de Surveillance a exprimé sa gratitude pour ses contributions en temps difficiles.
Suite au départ d'Evers, les responsabilités de la fonction CBO seront réparties entre d'autres fonctions du Directoire. Dr Christian Wojczewski, PDG d'Evotec, a remercié Evers pour son engagement et son leadership, soulignant particulièrement son soutien pendant la période de transition.
Evotec SE (Frankfurter Wertpapierbörse: EVT, NASDAQ: EVO) gab bekannt, dass Dr. Matthias Evers, Chief Business Officer, zum 01. Oktober 2024 zurücktreten wird, um außerhalb des Unternehmens neue Möglichkeiten zu verfolgen. Evers, der am 01. Mai 2022 ernannt wurde, spielte eine wichtige Rolle bei der Gründung des biologischen Segments von Evotec, Just - Evotec Biologics, und half dem Unternehmen, sich von einem Cyberangriff zu erholen. Der Aufsichtsrat sprach seine Dankbarkeit für seine Beiträge in schwierigen Zeiten aus.
Nach Evers' Rücktritt werden die Verantwortlichkeiten der CBO-Funktion auf andere Vorstandsfunktionen verteilt. Dr. Christian Wojczewski, CEO von Evotec, dankte Evers für sein Engagement und seine Führung, wobei er insbesondere seine Unterstützung während der Übergangszeit hervorhob.
- Smooth transition of CBO responsibilities across other Management Board functions
- Successful establishment of Evotec's biologics segment Just - Evotec Biologics
- Loss of key executive Dr Matthias Evers as Chief Business Officer
- Potential disruption in business operations due to leadership change
Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024
Distribution of responsibilities across other Management Board functions
HAMBURG, GERMANY / ACCESSWIRE / September 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced that its Chief Business Officer, Dr Matthias Evers, has decided to step down to pursue opportunities outside of Evotec. He will leave the Company effective 01 October 2024. Matthias was appointed Chief Business Officer of Evotec on 01 May 2022.
Prof. Dr Iris Löw-Friedrich, Chairwoman of the Supervisory Board of Evotec, said: "Over the past two-and-a-half years, Matthias has been instrumental in helping Evotec navigate challenging times. His many contributions - in particular establishing Evotec's biologics segment Just - Evotec Biologics as well as the recovery from the cyber-attack - will have a lasting impact. On behalf of Evotec's Supervisory Board, I would like to express our sincere gratitude to Matthias for his outstanding work over these past years. We wish Matthias every success in his future endeavours."
Dr Matthias Evers, Chief Business Officer of Evotec SE, commented: "Thank you to my amazing colleagues across all of Evotec - the passion for medicines that matter is inspiring and the people at Evotec make all the difference. While I have chosen to pursue a new path, I wish Evotec with all colleagues long-term success which I am confident the priority reset will bring."
Dr Christian Wojczewski, Chief Executive Officer of Evotec, added: "On behalf of the Management Board, I would like to thank Matthias for his commitment and dedication to Evotec for the past two-and-a-half years. He has shown great leadership in challenging times and his contributions will have lasting impact. On a personal note, I would like to thank Matthias for the great onboarding and his ongoing support as his responsibilities transition to other Management Board members."
As of 01 October, the responsibilities of the CBO function will be distributed across the other Management Board functions.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Media
Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
FAQ
When will Dr Matthias Evers step down as Evotec's Chief Business Officer?
How will Evotec handle the CBO responsibilities after Dr Evers' departure?
What were Dr Matthias Evers' key contributions to Evotec (EVO)?
When was Dr Matthias Evers appointed as Chief Business Officer of Evotec (EVO)?
